Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 1;29(7):679-693.e6.
doi: 10.1016/j.str.2021.04.001. Epub 2021 Apr 22.

Investigating GIPR (ant)agonism: A structural analysis of GIP and its receptor

Affiliations
Free article

Investigating GIPR (ant)agonism: A structural analysis of GIP and its receptor

Florent X Smit et al. Structure. .
Free article

Abstract

The glucose-dependent insulinotropic polypeptide (GIP) is a 42-residue metabolic hormone that is actively being targeted for its regulatory role of glycemia and energy balance. Limited structural data of its receptor has made ligand design tedious. This study investigates the structure and function of the GIP receptor (GIPR), using a homology model based on the GLP-1 receptor. Molecular dynamics combined with in vitro mutational data were used to pinpoint residues involved in ligand binding and/or receptor activation. Significant differences in binding mode were identified for the naturally occurring agonists GIP(1-30)NH2 and GIP(1-42) compared with high potency antagonists GIP(3-30)NH2 and GIP(5-30)NH2. Residues R1832.60, R1902.67, and R3005.40 are shown to be key for activation of the GIPR, and evidence suggests that a disruption of the K293ECL2-E362ECL3 salt bridge by GIPR antagonists strongly reduces GIPR activation. Combinatorial use of these findings can benefit rational design of ligands targeting the GIPR.

Keywords: GIP; GIPR; GPCR; antagonism; class B; incretin; molecular dynamics; mutation; structural analysis; truncation.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests This study was financially co-supported by Antag Therapeutics ApS. A.H.S.-U. is the CEO and co-founder of Antag Therapeutics ApS. M.M.R. is co-founder of Antag Therapeutics ApS and of Bainan Biotech ApS. M.M.R. is board member at Bainan Biotech. Patents related to this work: The rights to the two PCT applications above and any patents derived therefrom are licensed to Antag Therapeutics ApS, co-founded by A.H.S.-U. and M.M.R. The rights to the two PCT applications above and any patents derived therefrom are licensed to Bainan Biotech ApS, co-founded by M.M.R.

Publication types

MeSH terms

Substances

LinkOut - more resources